Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E12.02 EPS (ttm)5.40 Insider Own0.40% Shs Outstand1.33B Perf Week-4.25%
Market Cap86.16B Forward P/E9.57 EPS next Y6.78 Insider Trans-5.34% Shs Float1.29B Perf Month-7.08%
Income7.07B PEG- EPS next Q1.70 Inst Own81.40% Short Float0.99% Perf Quarter-11.99%
Sales22.28B P/S3.87 EPS this Y-22.80% Inst Trans-0.01% Short Ratio1.77 Perf Half Y-8.60%
Book/sh17.64 P/B3.68 EPS next Y-2.01% ROA2.40% Target Price87.40 Perf Year-14.20%
Cash/sh21.42 P/C3.03 EPS next 5Y-5.23% ROE7.40% 52W Range64.27 - 89.54 Perf YTD-9.49%
Dividend2.28 P/FCF17.25 EPS past 5Y36.20% ROI19.90% 52W High-27.59% Beta1.05
Dividend %3.52% Quick Ratio3.40 Sales past 5Y21.90% Gross Margin79.60% 52W Low0.89% ATR2.06
Employees10000 Current Ratio3.50 Sales Q/Q-14.10% Oper. Margin42.00% RSI (14)33.56 Volatility2.94% 2.99%
OptionableYes Debt/Eq1.19 EPS Q/Q-22.10% Profit Margin7.10% Rel Volume1.25 Prev Close65.12
ShortableYes LT Debt/Eq1.07 EarningsJan 24 AMC Payout180.20% Avg Volume7.19M Price64.84
Recom2.20 SMA20-4.89% SMA50-8.01% SMA200-11.14% Volume8,983,513 Change-0.43%
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Dec-18-18 07:20PM  Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod Zacks
02:01PM  Evofem Shares Up as Birth Control Gel Succeeds in Phase III Zacks
11:55AM  Biotech Stocks Gilead Sciences and Biogen Have Room to Bounce Back
10:20AM  Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer Zacks
09:15AM  What Happened With CAR-T Stocks in 2018 Motley Fool
07:17AM  3 Biotechs With Potential Blockbusters Near the Finish Line Motley Fool
Dec-17-18 05:45PM  Gilead Sciences (GILD) Stock Moves -0.69%: What You Should Know Zacks
12:28PM  5 Healthcare Stocks That Are Feeling Sick InvestorPlace
12:25PM  7 Major Pharmaceutical Stocks to Quarantine Now InvestorPlace
11:15AM  Goldman Called 2019 The Year of NASH, Others Say Not So Fast Bloomberg
Dec-16-18 09:07AM  2 Sets of Disasters Biotech Will Pay For in 2019 Motley Fool
Dec-15-18 03:49PM  Stocks That Fell to 3-Year Lows in the Week of Dec. 14
08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-14-18 12:32PM  Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus Zacks
10:25AM  AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals Zacks
07:59AM  5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride Zacks
07:00AM  Today's Research Reports on Trending Tickers: Axovant Sciences and Gilead Sciences ACCESSWIRE
Dec-13-18 09:26AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis Zacks
09:02AM  Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals Zacks
Dec-12-18 10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 03:55PM  Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO Zacks
02:49PM  New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James Benzinga
02:02PM  7 Stocks That Can Lead The Market Long Term Investopedia
12:07PM  The 10 Best Marijuana Stocks to Buy in 2019 InvestorPlace
09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
Dec-10-18 05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
04:13PM  Health Care Digest: Where were the women in Gilead's CEO search and more American City Business Journals
01:34PM  Gilead Sciences Names Roche's O'Day as CEO and Chairman
01:14PM  Gilead Needs More Than a Steady Hand From Its New CEO Bloomberg
12:17PM  Roche's Tecentriq Gets FDA Approval for First-Line NSCLC Zacks
11:42AM  [$$] Gilead Looks Outside to Revive Growth The Wall Street Journal
10:33AM  Dont Punish Gilead Stock for Doing Its Job InvestorPlace
10:10AM  Stocks - Apple, Boeing Slip in Premarket; Gilead Sciences, Tesla, Amazon Rise
09:33AM  Stocks Mixed, Dow Jones Dips As China Locks Apple Sales Investor's Business Daily
09:06AM  Gilead Gains, FedEx Falls and 5 More Morning Movers
07:57AM  Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know
07:35AM  New Research Coverage Highlights Skyworks Solutions, Virtus Investment Partners, Altria Group, Gilead Sciences, Arthur J. Gallagher, and BP p.l.c Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
04:19AM  [$$] US drugmaker Gilead poaches Roche executive Daniel ODay Financial Times
04:13AM  Roche vet named Gilead CEO and Genentech boss moves to Switzerland in shuffle of top Bay Area biotech execs American City Business Journals
02:43AM  Struggling Gilead Taps Roche Executive as New CEO The Wall Street Journal
02:10AM  Gilead Sciences snares Roche executive O'Day as CEO Reuters
01:53AM  Gilead Sciences snares Roche executive O'Day as CEO Reuters
01:00AM  Gilead Sciences Names Daniel ODay Chairman and Chief Executive Officer Business Wire
Dec-09-18 10:23PM  Roche Executive Daniel ODay to Be Named Gilead CEO The Wall Street Journal
09:52PM  Gilead Sciences to hire Roche executive O'Day as new CEO: source Reuters
08:43AM  Should Gilead Sciences Inc (NASDAQ:GILD) Be Part Of Your Income Portfolio? Simply Wall St.
07:00AM  Did Gilead Sciences Make an $11 Billion Blunder? Motley Fool
Dec-08-18 10:08PM  Hedge Funds Are Dumping Gilead Sciences, Inc. (GILD) Insider Monkey
08:09PM  Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-07-18 04:42PM  CEO of Chapel Hill firm talks 2 new partnerships with big pharma American City Business Journals
Dec-05-18 04:24PM  Why Oregon can now afford to treat more people with hepatitis C American City Business Journals
04:23PM  Gilead's (GILD) Harvoni and Descovy Get Approval in China Zacks
09:10AM  Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China Zacks
Dec-04-18 04:34PM  Amgen's BiTE Immunotherapies Show Promise in Early Studies Zacks
03:58PM  Gilead (GILD) Announces Data on CAR T Therapy Candidate Zacks
08:30AM  Chinas National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6 Business Wire
08:30AM  China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection Business Wire
Dec-03-18 08:00PM  Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Business Wire
05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
01:32PM  UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients Reuters
09:47AM  Shire's Takhzyro Gets European Nod for Hereditary Angioedema Zacks
09:41AM  FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate Zacks
Dec-02-18 06:57PM  High-cost Gilead cell therapy proves durable for some lymphoma patients Reuters
05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
12:04PM  Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma Business Wire
Nov-30-18 04:18PM  3 Top Dividend Stocks With Yields Over 3% Motley Fool
04:14PM  This Biotech Stock Could Launch Its First CRISPR Drug In 2022 Investor's Business Daily
09:56AM  Key Pharma Players With HIV Focus Ahead of World Aids Day Zacks
09:06AM  Bayer (BAYRY) to Restructure Business & Reduce Headcount Zacks
Nov-29-18 04:21PM  Merck (MRK) Receives Approval for 2 HIV Medicines in EU Zacks
08:38AM  Roche (RHHBY) to Acquire Jecure and Enter the NASH Space Zacks
08:33AM  Catalyst's Firdapse Receives FDA Approval for Rare Disease Zacks
Nov-28-18 05:48PM  Novartis (NVS) Receives EC Approval for Neulasta Biosimilar Zacks
05:09PM  Pfizer's Epilepsy Drug Lyrica Gets Pediatric Exclusivity Zacks
04:07PM  Celgene & Bluebird's CAR T Therapy Study Completes Enrollment Zacks
10:22AM  Aileron Inks Collaboration Deal With Pfizer for Cancer Combo Zacks
Nov-27-18 05:47PM  Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial Zacks
03:41PM  Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate Zacks
03:33PM  Bristol-Myers' Opdivo-Yervoy Combo Fails in Lung Cancer Trial Zacks
01:25PM  Roche buys U.S. biotech Jecure in race for liver disease drugs Reuters
11:22AM  5 Biotech Stocks to Scoop Up for Big Dividends InvestorPlace
10:44AM  Eyenovia Initiates Phase III Study for Mydriasis Candidate Zacks
08:54AM  Bayer's TRK Inhibitor Gets FDA Nod for Advanced Solid Tumors Zacks
08:00AM  Wall Street Wants the Best Patents, Not the Best Drugs Bloomberg
Nov-26-18 10:04AM  Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics American City Business Journals
08:25AM  Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth Zacks
Nov-25-18 02:40PM  Stocks That Fell to 3-Year Lows in the Week of Nov. 23
09:35AM  9 Policy Catalysts For Health Care Investors To Watch Before Year's End Benzinga
09:00AM  Better Buy: Gilead Sciences vs. Celgene Motley Fool
Nov-23-18 06:57AM  Novartis Gets Approval for Gene Therapy Luxturna in Europe Zacks
Nov-21-18 11:21AM  Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal Zacks
09:35AM  Should Value Investors Consider Gilead (GILD) Stock Now? Zacks
Nov-20-18 04:02PM  Gilead's Vemlidy Gets Approval in China for HBV Infection Zacks
09:10AM  Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint Zacks
Nov-19-18 02:33PM  Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta Zacks
12:23PM  Tesaro Stock Sinks in Aftermath of Sale Rumors InvestorPlace
09:43AM  Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension Zacks
Nov-18-18 10:00PM  China National Medical Products Administration (NMPA) Approves Gileads Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection Business Wire
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; and TARGET PharmaSolutions, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM